NCT05091333Completed
FASENRA Regulatory Postmarketing Surveillance in Korea
Source: ClinicalTrials.gov · Last updated 6 Feb 2026
Brief summary (registry, in English)
As part of a post approval commitment, the MFDS has requested a study to characterize safety in patients who are treated with FASENRA for severe eosinophilic asthma and/or eosinophilic granulomatosis with polyangiitis (EGPA) by physicians in normal clinical practice settings. This study is designed to confirm or assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of FASENRA under conditions of routine daily medical practice in Korea.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 51 (actual)
- First submitted
- 30 Sept 2021
- Start date
- 11 Mar 2022
- Primary completion date
- 6 Mar 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma, ANCA-associated vasculitis
- NCT number
- NCT05091333
What you commit to
- Study type: Observational
- Participants enrolled: 51
- From 11 Mar 2022 to the primary completion date, 6 Mar 2025
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hypersensitivity to the active substances or to any of the excipients
Other
- Current participation in any interventional trial
Who the study is looking for
- Patients aged 18 years and older
- Patients with severe asthma with an eosinophilic phenotype eligible for first time treatment with FASENRA according to the indication as indicated in the locally approved prescribing information
- Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Busan | South Korea | Unknown status |
| - Coordinator of this site? Confirm its status | Gangneung-si | South Korea | Unknown status |
| - Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| - Coordinator of this site? Confirm its status | Suwon | South Korea | Unknown status |
| - Coordinator of this site? Confirm its status | Ulsan | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.